Lexeo Therapeutics, Inc.’s (NASDAQ:LXEO) Lock-Up Period Will End on May 1st

Lexeo Therapeutics’ (NASDAQ:LXEO) lock-up period is set to expire on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Lexeo Therapeutics Stock Down 2.7 %

Shares of LXEO opened at $12.16 on Friday. Lexeo Therapeutics has a 12-month low of $9.00 and a 12-month high of $22.33. The stock has a 50-day moving average price of $14.37. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). As a group, analysts expect that Lexeo Therapeutics will post -3.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Eventide Asset Management LLC bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $40,298,000. Omega Fund Management LLC bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $28,955,000. Finally, Blackstone Inc. bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $9,342,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.